Search

Your search keyword '"T cell lymphoma -- Drug therapy"' showing total 22 results
Start Over Descriptor "T cell lymphoma -- Drug therapy"
22 results on '"T cell lymphoma -- Drug therapy"'

1. Tianjin University Reports Findings in Anticancer Agents (Solubility Enhancement of Anticancer Drug Belinostat Via the Co-crystallization Strategy: Synthesis, Characterization, and Antitumor Activity In Vitro Evaluation)

Subjects
Biopharmaceutics -- Licensing, certification and accreditation, Patient compliance -- Management, T cell lymphoma -- Drug therapy, Company business management, Health
Abstract

2023 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Anticancer Agents. According [...]

Published
2023

2. Studies in the Area of Peripheral T-Cell Lymphoma Reported from Sungkyunkwan University School of Medicine (Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of an Asian Phase 2 Study)

Subjects
Antineoplastic agents -- Testing, Arsenic compounds -- Testing, T cell lymphoma -- Drug therapy, Antimitotic agents -- Testing, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in peripheral T-cell lymphoma. According to news reporting [...]

Published
2023

3. Soligenix announces $1.5M NCI SBIR grant award

Subjects
United States. National Cancer Institute -- Powers and duties, United States. National Institutes of Health -- Powers and duties, T cell lymphoma -- Drug therapy, Biotechnology industries -- Government finance, Business, News, opinion and commentary
Abstract

Soligenix announced that the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, has awarded Soligenix a Small Business Innovation Research, or SBIR, grant of [...]

Published
2017

4. Methoxsalen, oral

Subjects
Psoriasis -- Drug therapy, Vitiligo -- Drug therapy, Methoxsalen -- Dosage and administration -- Complications and side effects, T cell lymphoma -- Drug therapy, Health
Abstract

meth-OKS-a-len What are other names for this medicine? Type of medicine: psoralen Generic and brand names: methoxsalen, oral; Oxsoralen-Ultra, 8-MOP, oral What is this medicine used for? This medicine is [...]

Published
2010

5. Methoxsalen, injection

Subjects
Methoxsalen -- Dosage and administration -- Complications and side effects, T cell lymphoma -- Drug therapy, Health
Abstract

meth-OKS-a-len What are other names for this medicine? Type of medicine: psoralen Generic and brand names: methoxsalen, injection; Uvadex What is this medicine used for? This medicine is given by [...]

Published
2010

6. Denileukin diftitox, injection

Subjects
T cell lymphoma -- Drug therapy, Health
Abstract

den-ih-LOO-kin DIF-tih-toks What are other names for this medicine? Type of medicine: antineoplastic (anticancer); chemotherapy Generic and brand names: denileukin diftitox, injection; Ontak What is this medicine used for? This [...]

Published
2010

7. Bexarotene, oral

Subjects
T cell lymphoma -- Drug therapy, Health
Abstract

beks-AYR-oh-teen What are other names for this medicine? Type of medicine: synthetic retinoid; anticancer; chemotherapy Generic and brand names: bexarotene, oral; Targretin What is this medicine used for? This medicine [...]

Published
2010

8. Subcutaneous panniculitis-like T-cell cutaneous lymphoma

Author

Singh, Avninder, Kumar, Joginder, Kapur, Sujala, and Ramesh, V.

Subjects
T cells -- Health aspects, T cells -- Genetic aspects, T cells -- Research, T cell lymphoma -- Diagnosis, T cell lymphoma -- Drug therapy, T cell lymphoma -- Genetic aspects, T cell lymphoma -- Case studies, Chemotherapy -- Health aspects, Cancer -- Chemotherapy, Cancer -- Health aspects
Abstract

Byline: Avninder. Singh, Joginder. Kumar, Sujala. Kapur, V. Ramesh Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare cytotoxic T-cell lymphoma classified in the World Health Organization-European Organization for Research [...]

Published
2008

9. FDA fast tracks Rx for hard-to-treat peripheral T-cell lymphoma

Subjects
Allos Therapeutics Inc. -- Product development, Pharmaceutical industry -- Product development, T cell lymphoma -- Drug therapy, Health, Folotyn (Medication) -- Licensing, certification and accreditation, Folotyn (Medication) -- Dosage and administration
Abstract

Allos Therapeutics has received accelerated FDA approval for Folotyn (pralatrexate) as a single-agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma. The company's new drug application was based [...]

Published
2009

10. Pralatrexate approved for relapsed or refractory peripheral t-cell lymphoma

Subjects
Folotyn (Medication) -- Licensing, certification and accreditation, Folotyn (Medication) -- Dosage and administration, T cell lymphoma -- Drug therapy
Abstract

The US Food and Drug Administration (FDA) has granted accelerated approval for pralatrexate injection (Folotyn) for use as a single agent for the treatment of patients with relapsed or refractory [...]

Published
2009

11. Yaupon locks up phase II Clearazide trial

Subjects
Antimitotic agents -- Product development, Antimitotic agents -- Dosage and administration, Antineoplastic agents -- Product development, Antineoplastic agents -- Dosage and administration, Pharmaceutical industry -- Product development, T cell lymphoma -- Drug therapy, Health
Abstract

Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma. The randomized study, slated for completion in 2010, has enrolled 260 [...]

Published
2009

12. JAPAN'S MUNDIPHARMA EYES CLINICAL TRIALS FOR CANCER DRUG

Subjects
Purdue Pharma L.P. -- Product development, BioCryst Pharmaceuticals Inc. -- Product development, Antineoplastic agents -- Product development, Orphan drugs -- Product development, Non-Hodgkin's lymphomas -- Drug therapy, Health care industry -- Product development, Cancer -- Care and treatment, Clinical trials, T cell lymphoma -- Drug therapy, Antimitotic agents -- Product development, Pharmaceutical industry -- Product development, Health care industry, Business, general
Abstract

TOKYO, July 9 Asia Pulse - Mundipharma KK, part of the group of associated firms that includes U.S. drug company Purdue Pharma, will begin phase I clinical trials as early [...]

Published
2008

13. Istodax

Subjects
Celgene Corp. -- Product development, Romidepsin -- Dosage and administration -- Licensing, certification and accreditation, Antineoplastic agents -- Dosage and administration -- Licensing, certification and accreditation, T cell lymphoma -- Drug therapy, Antimitotic agents -- Dosage and administration -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Istodax (Medication) -- Licensing, certification and accreditation -- Dosage and administration
Abstract

Romidepsin for injection (Istodax, Celgene) was granted expanded approval to treat peripheral T-cell lymphoma in patients who have received at least 1 prior therapy. Istodax is also approved for treating [...]

Published
2011

14. Istodax

Subjects
Celgene Corp. -- Product information, Romidepsin -- Product information, T cell lymphoma -- Drug therapy, Pharmaceutical industry -- Product information, Pharmaceuticals and cosmetics industries, Istodax (Medication) -- Product information
Abstract

Romidepsin (Istodax, Celgene) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior [...]

Published
2011

15. Darinaparsin (Zinapar or ZIO-101, Ziopharm Oncology)

Subjects
Antineoplastic agents -- Health aspects -- Product information, Biotechnology industry -- Product information, T cell lymphoma -- Drug therapy, Antimitotic agents -- Health aspects -- Product information, Pharmaceuticals and cosmetics industries, Zinapar (Medication) -- Product information
Abstract

Darinaparsin (Zinapar or ZIO-101, Ziopharm Oncology) for the treatment of peripheral T-cell [...]

Published
2010

16. Rare lymphoma gets first drug

Subjects
T cell lymphoma -- Drug therapy, Pharmaceutical industry -- Product development -- Licensing, certification and accreditation, Health, Health care industry
Abstract

Pralatrexate has been approved for use as a single agent for treating patients with refractory or relapsed peripheral T-cell lymphoma, the FDA announced. The first treatment approved for this rare, [...]

Published
2009

17. Romidepsin (Gloucester) for the treatment of cutaneous T-cell

Subjects
Antimitotic agents -- Licensing, certification and accreditation, Antineoplastic agents -- Licensing, certification and accreditation, Pharmaceutical industry -- Product development, T cell lymphoma -- Drug therapy, Pharmaceuticals and cosmetics industries
Abstract

Romidepsin (Gloucester) for Dumlanethe treatment of cutaneous T-cell [...]

Published
2009

18. Folotyn

Subjects
Allos Therapeutics Inc. -- Product development, Pharmaceutical industry -- Product development, T cell lymphoma -- Drug therapy, Pharmaceuticals and cosmetics industries, Folotyn (Medication) -- Licensing, certification and accreditation
Abstract

Pralatrexate (Folotyn, Allos) for the treatment of relapsed or refractory peripheral T-cell [...]

Published
2009

19. FDA grants full approval to ONTAK® (denileukin diftitox) for use in patients with CTCL

Subjects
Eisai Corporation of North America Inc. -- Reports -- Licensing, certification and accreditation, Financial services industry -- Reports -- Licensing, certification and accreditation, T cell lymphoma -- Drug therapy, Financial services industry, Health, Ontak (Medication) -- Licensing, certification and accreditation -- Dosage and administration -- Reports
Abstract

Eisai Corporation of North America announced that the U.S. Food and Drug Administration (FDA) has approved an efficacy supplemental biologics license application (sBLA) for ONTAK® (denileukin diftitox) solution for intravenous [...]

Published
2009

20. Remicade OK'd for kids

Subjects
Centocor Inc. -- Labeling -- Product development -- Licensing, certification and accreditation, Infliximab -- Licensing, certification and accreditation -- Product development -- Labeling, Medical test kit industry -- Labeling -- Product development -- Licensing, certification and accreditation, Medical equipment and supplies industry -- Labeling -- Product development -- Licensing, certification and accreditation, T cell lymphoma -- Drug therapy, Crohn's disease -- Drug therapy, Health, Remicade (Medication) -- Licensing, certification and accreditation -- Labeling
Abstract

Remicade (infliximab) has gained an indication for reducing the signs and symptoms and inducing and maintaining clinical remission in children with moderately to severely active Crohn's disease who have had [...]

Published
2006

21. Pharmacology Watch

Subjects
United States. Food and Drug Administration, Pharmacology -- Reports, Gallstones -- Risk factors, Cardiovascular diseases -- Risk factors, Omeprazole -- Chemical properties, Statins -- Health aspects, Niacin -- Health aspects, Stroke (Disease) -- Risk factors, Cholesterol, HDL -- Health aspects, Clopidogrel -- Chemical properties, Darbepoetin alfa -- Health aspects, Neuralgia -- Drug therapy, Capsaicin -- Licensing, certification and accreditation, Romidepsin -- Licensing, certification and accreditation, T cell lymphoma -- Drug therapy, Health
Published
2010

22. CHOP-Campath for PTCL

Subjects
T cell lymphoma -- Drug therapy, Chemotherapy -- Methods, Chemotherapy -- Evaluation, Cancer -- Chemotherapy, Cancer -- Methods, Cancer -- Evaluation, Health, Campath (Medication) -- Dosage and administration
Abstract

CHOP-Campath for PTCL Abstract & Commentary By Andrew Artz, MD, MS, Division of Hematology/Oncology, University of Chicago, Chicago, IL. Dr. Artz reports no financial relationship to this field of study. [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results